Transforming translational research: CANscriptTM – A better predictive model for oncology
ABOUT THIS WEBINAR
In this webinar, speaker Mark Paris, PhD will be discussing a recent study evaluating a cohort of HNSCC patient tumours treated with anti-PD1 using CANscript™. He will also be reviewing the results of this study as a means of investigating predictors of clinical response and identifying mechanisms of resistance.
Delineation of the intra-tumour microenvironment in a dynamic, spatio-temporal setting is critical for investigating the activity and efficacy of candidate oncology drugs. The majority of solid cancers contain unorganised, highly-complex microenvironment wherein a dysregulated phenotypic impacts treatment outcomes at a personalised level.
We have developed and validated a fully human ex-vivo platform technology (CANscript™) using patient material (tumour, autologous ligands and immune cells) to explore the mechanism of and predict efficacy for clinically-directed compounds across several drug classes (Nat Comm., 6:6169:1-14 2015).
Drugs that modulate the immune system have been shown to be very effective in some patients. Tumour Infiltrating Lymphocytes are often required for the function of these drugs. In order to understand the role of functional immune phenotypes, we evaluated a cohort of HNSCC patient tumours treated with anti-PD1 using CANscript™.
This session will review results of this study as a means of investigating predictors of clinical response and identifying mechanisms of resistance.
Mark Paris, PhD, Associate Director, Translational Applications, Mitra Biotech
Mark is the technical lead for Mitra’s biopharma marketing effort and works with clients to craft custom solutions for their drug development needs. He spent 16 years in commercial antibody discovery and clinical development focusing on immuno-oncology. He has >12 years of experience running core molecular and immunohistochemistry labs. He is a graduate of Case Western Reserve University with a Ph.D. in Genetics.